New Retina Radio by Eyetube

Jaksot

• 
  Spotlight on UNITY® VCS: Breaking New Ground 10.09.2026 13min

  In this episode of RetinaLive focused on UNITY® VCS|CS, Jay Sridhar, MD is joined by Nina Berrocal, MD for a forward-looking discussion on adopting next-generation surgical technology. The conversation explores how UNITY® VCS is enabling innovation in a new retina practice setting, with a focus on fluidics stability, integrated anterior and posterior segment capabilities, and enhanced intraoperative efficiency. Through real-world perspectives, the episode highlights the role of advanced technology in simplifying surgical workflows, and supporting the training of the next generation of retina surgeons. For Important Product Information, visit unityvcs.com. Speakers are paid Alcon consultants. The views expressed are their own. Disclaimers: 4:05: Based on Bench Data. UNITY® VCS with HYPERVIT® 30k cpm vitrectomy probe vs. CONSTELLATION® VS with HYPERVIT® 20k cpm vitrectomy probe 6:13: *Mean fluctuation at flow vs. setpoint of 2.36 ± 2.13, 4.19 ± 1.97, 1.84 ± 2.82, and 2.13 ± 2.86 mmHg during phacoemulsification, irrigation/aspiration (IA), vitrectomy, and extrusion/fragmentation, respectively. IOP setpoint as low as 16 mmHg (posterior) and 20 mmHg (anterior) without exceeding a mean fluctuation of 4.19 ± 1.97 mmHg 9:08: MSLP(4) is 3 times faster than SSLP References: 1. UNITY™ VCS and CS User Manual Unity Phaco Handpiece Directions for Use.  2. Alcon data on file 2024 (REF-24615) 3. Alcon data on file 2024 (REF-24379) 4. Alcon data on file 2024 (REF-24576) 5. Alcon Data on File (REF-27800) 6. UNITY™ VCS and CS User Manual 7. Alcon data on file 2024. (REF-24899)   Sponsored by Alcon, Inc. © 2026 Alcon Inc. 07/26 US-UVC-2600112
• 
  ASRS '26: ArMaDa/GARDian Results and Real-World YAG Complication Incidence 27.08.2026 16min

  Can a single molecule treat both GA and Stargardt Disease? And if so, how far along is the research? Jay Chhablani, MD, joins New Retina Radio to share data from ArMaDa and GARDian, which assessed OCU410 (Ocugen) in geographic atrophy and Stargardt disease, respectively. And Jordan Deaner, MD, sits down to discuss his research on real-world retinal tears and detachments following YAG capsulotomy. What are the actual incidence rates? And what risk factors were identified? Stick with us to find out.  
• 
  Comparing Ocular AEs in Next-Gen Treatments 20.08.2026 13min

  What can pharmacovigilance data tell us about the post-marketing safety profiles of anti-VEGF agents, and where do those signals fall short? In this episode of New Retina Radio Journal Club with VBS, Katherine Talcott, MD, moderates a discussion with Akshay Thomas, MD, and Nita Valikodath, MD, MS, on a 2026 study comparing ocular adverse event reporting for aflibercept 2 mg (Eylea, Regeneron), aflibercept 8 mg (Eylea HD, Regeneron), and faricimab (Vabysmo, Genentech/Roche) using the FDA Adverse Event Reporting System. The group examines distinct signal profiles for each agent and makes the case for why these findings should be viewed as hypothesis-generating rather than evidence of causality.
• 
  The Story Behind LYTENAVA™: From FDA Approval to Retina Practice 18.08.2026 11min

  In this episode of New Retina Radio, host Barry Kuppermann, MD, PhD, sits down with Bob Jahr, CEO of Outlook Therapeutics, to discuss the FDA approval of LYTENAVA™ (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab formulation for nAMD.1,2 They explore the regulatory journey over the course of more than 8 years,3 the rigorous FDA review process,4 manufacturing and product quality, commercialization plans, payer considerations, and future development. Please see the Important Safety Information and full US Prescribing Information for LYTENAVA. Intended for a US audience only. Sponsored by Outlook Therapeutics References 1. Harp MD. FDA approves Outlook Therapeutics' LYTENAVA for the treatment of wet AMD. Ophthalmology Times. Published July 24, 2026. Accessed July 28, 2026. https://www.ophthalmologytimes.com/view/fda-approves-outlook-therapeutics-lytenava-for-the-treatment-of-wet-amd 2. LYTENAVA™ (bevacizumab-vikg) prescribing information. Outlook Therapeutics; 2026. 3. Outlook Therapeutics. Oncobiologics changes name to Outlook Therapeutics; announces next steps in executing ONS-5010 clinical and regulatory strategy. Published December 3, 2018. Accessed July 24, 2026. https://ir.outlooktherapeutics.com/news-releases/news-release-details/oncobiologics-changes-name-outlook-therapeutics-announces-next 4. US Food and Drug Administration. The FDA's drug review process: ensuring drugs are safe and effective. Updated January 4, 2018. Accessed July 28, 2026. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective
• 
  The Fellow Eye: Episode 6 13.08.2026 41min

  Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Monia Reding, MD, a retina fellow at Casey Eye Institute, and Benjamin Young, MD, assistant professor of Ophthalmology at Casey Eye Institute, to talk about lasers. They share the pros and cons of slit-lamp laser and indirect, ergonomics, laser settings, difficult scenarios, and the personal experiences that shape their practice patterns.
• 
  ASRS '26: SOL-1 and TRUCKEE at 4.5 Years 05.08.2026 24min

  Could TKIs be the game-changing therapy that makes wet AMD treatment less burdensome? Dilsher Dhoot, MD, joins the show to examine the SOL-1 study, a superiority study assessing the safety, efficacy, and durability of axitinib (Axpaxli, Ocular Therapeutix) for the treatment of wet AMD. And Carl Danzig, MD, stops by to deliver the 4.5-year data from TRUCKEE, which tells us how real-world patients with wet AMD perform when dosed with faricimab (Vabysmo, Genentech/Roche). How are patients doing after 3, 6, or even 9 doses? Stick with us to find out.
• 
  New Retina Radio Journal Club w/ VBS: Clinical Features and Outcomes of IOFB Removal 16.07.2026 16min

  What do large registry data reveal about outcomes after intraocular foreign body removal, and how should those findings shape surgical planning and patient counseling? In this episode of New Retina Radio Journal Club with VBS, Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, on a 2025 IRIS Registry analysis of nearly 4,800 eyes. The group reviews the delayed timeline of visual recovery, the risk of late complications, and practical guidance on staging surgical intervention and setting realistic expectations in complex trauma cases.
• 
  Barriers to Care, Patient Education, and Treatment Decisions in Geographic Atrophy 08.07.2026 16min

  What stands between a patient with geographic atrophy and consistent, effective treatment? And how do clinicians bridge that gap? In episode 3 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, address injection burden, insurance hurdles, and the role of patient education tools in supporting adherence. The group also weighs the potential for AI to guide treatment decisions and track progression, then works through a hypothetical case of an 82-year-old caregiver with bilateral diffuse trickling GA who is not yet motivated to pursue treatment.
• 
  Evolving Practice Patterns and Dosing Strategies in Geographic Atrophy 08.07.2026 18min

  How have 3 years of real-world experience with complement inhibition changed when and how retina specialists treat GA? In episode 2 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, examine how referral patterns, safety data, and extension study findings have shifted their approach to early treatment. The group then works through a hypothetical case of an active 73-year-old patient with extrafoveal GA and intermediate AMD in the fellow eye, exploring how lesion characteristics, CNV risk counseling, and months-long travel schedules factor into the treatment decision.
• 
  Biomarkers, Imaging, and Early Treatment Decisions in Geographic Atrophy 08.07.2026 13min

  Which imaging biomarkers matter most at diagnosis of GA, and how should they shape the decision to treat? In episode 1 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, review the practical role of fundus autofluorescence and OCT in identifying high-risk GA, discuss ellipsoid zone integrity as an emerging endpoint, and work through a hypothetical case of an active, motivated patient with bilateral extrafoveal GA and good vision to explore how lifestyle, lesion characteristics, and patient education factor into early treatment decisions.
• 
  The Fellow Eye: Episode 5 01.07.2026 39min

  Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Omesh P. Gupta, MD, retina specialist at Wills Eye Hospital, and Shane Griffin, MD, MCR, vitreoretinal surgery fellow at the University of California San Diego Shiley Eye Institute, to discuss scleral-fixating secondary IOLs. They share pearls for implantation success, advanced techniques, and tricks for handling complicated cases.
• 
  Retinal Perfusion, Sensitivity, and Function in DR 26.06.2026 15min

  Does retinal capillary non-perfusion reliably predict functional vision loss in DR? And does the answer change how retina specialists treat it? In this episode of New Retina Radio Journal Club with VBS, Barton Blackorby, MD; Katherine Talcott, MD; and Hong-Uyen Hua, MD, discuss a prospective longitudinal cohort study examining the association between retinal sensitivity and perfusion over 2 years in patients with DR.
• 
  Spotlight on UNITY® VCS: Experience Extraordinary 22.06.2026 29min

  In this episode of RetinaLIVE, Kourous Rezaei, MD is joined by Lejla Vajzovic, MD, FASRS and Aleksandra Rachitskaya, MD, FASRS to discuss their experiences with UNITY® VCS in vitreoretinal surgery. The conversation covers instrument design, workflow, training and the integration of new technology in clinical practice, offering perspectives on collaboration and adapting to evolving surgical tools.  For Important Product Information, visit unityvcs.com. Featured surgeons are paid Alcon consultants. The views expressed are their own. Disclaimers: 1:15, 19:31, 26:25: Compared to CONSTELLATION® Vision System. Based on bench data. 1:47, 2:15, 2:42, 3:19, 9:55: Compared to HYPERVIT 20K 2:15, 2:21, 7:24: Based on bench data. For both 25 Ga and 27 Ga vitrectomy probes. 7:24, 7:54, 18:46: Versus Alcon’s Non-Dynamic Stiffener 27+ technology 9:55, 12:21: When the Dynamic Stiffener is fully retracted 16:20: MSLP(4) is 3 times faster than SSLP 23:58: Compared to CONSTELLATION® Vision System. Based on bench data. Mean fluctuation at flow vs. setpoint of 2.36 ± 2.13, 4.19 ± 1.97, 1.84 ± 2.82, and 2.13 ± 2.86 mmHg during phacoemulsification, irrigation/aspiration (IA), vitrectomy, and extrusion/fragmentation, respectively. †IOP setpoint as low as 16 mmHg (posterior) and 20 mmHg (anterior) without exceeding a mean fluctuation of 4.19 ± 1.97 mmHg.   References: Hypervit Directions for Use. TetraSpot Multi-spot Laser Probe Directions for Use. UNIFEYE Directions for Use. Alcon Data on File, 2024. [REF-24644] Alcon Data on file, 2024. [REF-24615] Alcon Data on File, 2024. [REF-24379] Alcon Data on File, 2024. [REF-24615] Alcon Data on File, 2024. [REF-24576] UNITY VCS and CS User Manual. Alcon Data on File, 2024. [REF-27800] Gerardo GS, Chow DR. Shovel and Cut Technique: Beveled Vitrectomy Probes to Address Diabetic Tractional Retinal Detachments. Retina. 2023. 1;43(7):1207-1208 Berrocal MH. All-probe vitrectomy dissection techniques for diabetic tractional retinal detachments: Lift and shave. Lift and Shave. Retina. 2018 Sep;38 Suppl 1:S2-S4. González-Saldivar G, Chow DR. The Shovel and cut technique: Beveled vitrectomy probes to address diabetic tractional retinal detachments. Retina. Published online ahead of print. doi:10.1097/IAE.0000000000002938. Po-Lin Chen, Yan-Ting Chen, San-Ni Chen, Comparison of 27-gauge and 25-gauge vitrectomy in the management of tractional retinal detachment secondary to proliferative diabetic retinopathy. Plos One. 2021:16(3) Kasi SK, Hsu J, Hariprasad SM. Making the Jump to 27-Gauge Vitrectomy: Perspectives. Ophthalmic Surgery, Lasers and Imaging Retina. 2017;48(6):450-456. doi:10.3928/23258160-20170601-02 James M. Lai, et all. Mechanical Property Comparison of 23-, 25- and 27-gauge Vitrectors Across Vitrectomy Systems. Ophthalmology Retina. 2022. Alcon Data on File, 2024. [REF-09694] Alcon Data on File, 2024. [REF-25374] Alcon Data on File, 2024. [REF-24899] Scarfone HA, Rodriguez EC, Rufiner MG, Riera JJ, Fanego SE, Charles M, Albano R. Vitreous-lens interface changes after cataract surgery using active fluidics and active sentry with high and low infusion pressure settings. J Cataract Refract Surg. 2024 Apr 1;50(4):333-338. doi: 10.1097/j.jcrs.0000000000001359. PMID: 37938025; PMCID: PMC10959530. Liu Y, Hong J, Chen X. Comparisons of the clinical outcomes of Centurion® active fluidics system with a low IOP setting and gravity fluidics system with a normal IOP setting for cataract patients with low corneal endothelial cell density. Front Med (Lausanne). 2023 Nov 23;10:1294808. doi: 10.3389/fmed.2023.1294808. PMID: 38076276; PMCID: PMC10704024. Taiki Kokubun, et al. Verification for the usefulness of normal tension cataract surgery. Hanga Beres, et al. Does low infusion pressure microinsision cataract surgery (LIPMiCS) reduce the frequency of post-occulsion breaks? 2022. 66(2) Rauen MP, Joiner H, Kohler RA, O'Connor S. Phacoemulsification using an Active Fluidics System at Physiologic versus High IOP: Impact on Anterior and Posterior Segment Physiology. J Cataract Refract Surg. 2024 Apr 8. doi: 10.1097/j.jcrs.0000000000001457. Epub ahead of print. PMID: 38595209.   © 2026 Alcon Inc.   04/26   US-UVC-2600054
• 
  ARVO '26: TKIs for Wet AMD and How We Got to the AI Era of Research 18.06.2026 32min

  TKIs are all the rage. But what do the data tell us about their ability to effectively treat wet AMD? Akshay Thomas, MD, outlines findings from DAVIO 2, the phase 2 study assessing the safety and efficacy of EYP-1901 (EyePoint Pharmaceuticals) for the treatment of wet AMD. And Aaron Lee, MD, MSCI, and Cecelia Lee, MD, MS, recap their Cogan Award Lecture from this year’s ARVO annual meeting. Hear how they envision a future of ophthalmic research driven by AI and machine learning—and how they know we can only get there by looking back at where we've been.
• 
  Spotlight on UNITY® VCS Dynamic Stiffener 27+ 15.06.2026 21min

  In this episode of RetinaLIVE, Christina Weng, MD, MBA, FASRS is joined by Mrinali Gupta, MD, FASRS and Omesh Gupta, MD, MBA for a conversation focused on the evolution of 27-gauge instrumentation in vitreoretinal surgery with the UNITY® VCS platform. The panel discusses their experiences adapting to new tools and techniques. Listeners will hear perspectives on integrating new technology and the ongoing refinement of microsurgical approaches.  For Important Product Information, visit unityvcs.com.Featured surgeons are paid Alcon consultants. The views expressed are their own. Disclaimers: 1:27: Compared to CONSTELLATION® HYPERVIT 20K vitrectomy probe Based on bench data 3:52, 4:14, 6:28, 7:33, 7:59: Versus Alcon’s Non-Dynamic Stiffener 27+ technology 10:14, 11:33, 12:19: Compared to GRIESHABER® REVOLUTION® Handle References: Alcon Data on File, 2024. [REF-24615] Alcon Data on File, 2024. [REF-24379] Alcon Data on File, 2024. [REF-24576] UNITY Phaco Handpiece – Directions for Use. UNITY VCS and CS User Manual Alcon Data on File, 2020. [REF-09694] Alcon Data on File, 2024. [REF-24644] Alcon Data on File, 2024. [REF-25563] Alcon Data on File, 2024. [REF-25994] Alcon Data on File, 2024. [REF-09956] Alcon Data on File, 2019. [REF-09958] Alcon Data on File, 2021. [REF-02476] Alcon Data on File, 2023. [REF-02478] Alcon Data on FIle, 2023. [REF-04981] Alcon Data on File, 2018. [REF-12829] Alcon Data on File, 2017. [REF-09581] Alcon Data on File, 2018. [REF-09577] Alcon Data on File, 2019. [REF-09576] Alcon Data on File, 2018. [REF-09579] Alcon Data on File, 2023. [REF-09955] Alcon Data on File, 2021. [REF-09951] Alcon Data on File, 2023. [REF-09952] Alcon Data on File, 2023. [REF-09952] Alcon Data on File, 2020. [REF-09954] Finesse Flex Loop Directions for Use. © 2026 Alcon Inc.   04/26   US-UVC-2600052
• 
  Spotlight on UNITY® VCS: UNITY for All 08.06.2026 23min

  Centered on the UNITY® VCS platform, this RetinaLIVE episode features Sarwar Zahid, MD, FASRS moderating a discussion with John Kitchens, MD and Matthew Cunningham, MD, FASRS. The panel shares firsthand experiences with UNITY® VCS. Listeners will discover practical insights on how the technology support both seasoned surgeons and fellows. For Important Product Information, visit http://unityvcs.com Featured surgeons are paid Alcon consultants. The views expressed are their own. Disclaimers: 1:52: Based on bench data 3:28: MSLP(4) is 3 times faster than SSLP 8:53, 9:16: For posterior segment surgeries/poster cassette pack. (P
• 
  ARVO '26: DME Delphi Study and RHONE-X 04.06.2026 28min

  Gaining global consensus on DME needs will dictate the terms of future drug development. Can the findings from the DME AWARE Delphi study help? Baruch Kuppermann, MD, PhD, joins the show to review the findings from a 25-doctor panel of global experts. What did they conclude regarding the unmet needs in DME?
• 
  New Retina Radio Journal Club w/ VBS: Observation vs. Vitrectomy for Floaters 15.05.2026 20min

  When do symptomatic vitreous floaters warrant surgery, and when is observation sufficient? In this episode of New Retina Radio Journal Club with VBS, host Kyle Kovacs, MD, joins Matthew Starr, MD, and Neda Valikodath, MD, to review a major study on vision-degrading myodesopsias from vitreous floaters. They then debate the risks and value of limited refractive vitrectomy for select patients in real-world settings, and review their protocols for patients who present with floaters. 
• 
  The Fellow Eye: Episode 4 11.05.2026 43min

  Co-hosts David Fell, MD, and Justin C. Muste, MD, sit down with Allen C. Ho, MD, director of Retina Research at Wills Eye Hospital, and Curtis Heisel, MD, MBA, a vitreoretinal surgery fellow at the University of California San Diego, to discuss the gene therapy landscape in retina. They share their journeys in the space, the therapies under investigation, and how fellows can get involved. 
• 
  Extending Treatment Efficacy in Wet AMD 08.05.2026 31min

  Podcast moderator Lejla Vajzovic, MD, sits down with Robert L. Avery, MD; Carl D. Regillo, MD; and Durga S. Borkar, MD, MMCi, to explore how new therapies hold promise for extending treatment efficacy in patients with wet AMD. They touch on various drug delivery platforms, gene therapy, tyrosine kinase inhibitors, and the challenges of drug development and approval.